WO2005078117A3 - Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6) - Google Patents

Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6) Download PDF

Info

Publication number
WO2005078117A3
WO2005078117A3 PCT/EP2005/001136 EP2005001136W WO2005078117A3 WO 2005078117 A3 WO2005078117 A3 WO 2005078117A3 EP 2005001136 W EP2005001136 W EP 2005001136W WO 2005078117 A3 WO2005078117 A3 WO 2005078117A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
klk6
disorders
kallikrein
therapeutics
Prior art date
Application number
PCT/EP2005/001136
Other languages
English (en)
Other versions
WO2005078117A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Priority to EP05707200A priority Critical patent/EP1718975A2/fr
Publication of WO2005078117A2 publication Critical patent/WO2005078117A2/fr
Publication of WO2005078117A3 publication Critical patent/WO2005078117A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96458—Factor XII (3.4.21.38)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une KLK6 humaine associée à des inflammations, des maladies des muscles-squelette, des maladies hématologiques, des maladies gastro-intestinales et du foie, des troubles neurologiques, des troubles urologiques, des troubles cardio-vasculaires, le cancer, des maladies métaboliques et des maladies dermatologiques. L'invention concerne également des dosages destinés à l'identification de composés utiles dans le traitement ou la prévention des inflammations, des maladies des muscles-squelette, des maladies hématologiques, des maladies gastro-intestinales et du foie, des troubles neurologiques, des troubles urologiques, des troubles cardio-vasculaires, du cancer, des maladies métaboliques et des maladies dermatologiques. L'invention concerne enfin des composés se liant à l'activité de KLK6 et/ou activant ou inhibant celle-ci, ainsi que des compositions pharmaceutiques renfermant de tels composés.
PCT/EP2005/001136 2004-02-18 2005-02-04 Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6) WO2005078117A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05707200A EP1718975A2 (fr) 2004-02-18 2005-02-04 Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04003589 2004-02-18
EP04003589.1 2004-02-18

Publications (2)

Publication Number Publication Date
WO2005078117A2 WO2005078117A2 (fr) 2005-08-25
WO2005078117A3 true WO2005078117A3 (fr) 2006-04-20

Family

ID=34854560

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/001136 WO2005078117A2 (fr) 2004-02-18 2005-02-04 Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6)

Country Status (2)

Country Link
EP (1) EP1718975A2 (fr)
WO (1) WO2005078117A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008156418A1 (fr) * 2007-06-19 2008-12-24 Astrazeneca Ab Procédé de criblage ou de diagnostic du syndrome de post-poliomyélite et de la fibromyalgie
US8530427B2 (en) 2010-09-30 2013-09-10 Mayo Foundation For Medical Education And Research Methods for modulating resistance to apoptosis using KLK6
BR112013032132A2 (pt) * 2011-06-17 2016-11-22 Univ Johns Hopkins "uso de peptidase da família calicreína, de agente que aumenta a sua expressão ou de células que apresentam expressão ou atividade de rheb reduzida para prevenção ou tratamento de diabetes e distúrbio metabólico e aumento da sensibilidade à insulina, bem como métodos para determinar se composto de teste é agente terapêutico provável no tratamento de diabetes"
FR2983868B1 (fr) * 2011-12-07 2016-09-02 Oreal Klk6 comme biomarqueur du cuir chevelu
US20160000791A1 (en) 2014-07-07 2016-01-07 Mayo Foundation For Medical Education And Research Par1 modulation to alter myelination

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002035232A2 (fr) * 2000-10-27 2002-05-02 Mount Sinai Hospital Methode de detection ddu cancer de l'ovaire
US20020182644A1 (en) * 2000-10-27 2002-12-05 Mount Sinai Hospital Methods for detecting Alzheimers disease
WO2003047572A1 (fr) * 2001-12-04 2003-06-12 Merck Patent Gmbh Utilisation de composes 1-phenyl-oxazolidin-2-one comme inhibiteurs de la protease m

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002035232A2 (fr) * 2000-10-27 2002-05-02 Mount Sinai Hospital Methode de detection ddu cancer de l'ovaire
US20020182644A1 (en) * 2000-10-27 2002-12-05 Mount Sinai Hospital Methods for detecting Alzheimers disease
WO2003047572A1 (fr) * 2001-12-04 2003-06-12 Merck Patent Gmbh Utilisation de composes 1-phenyl-oxazolidin-2-one comme inhibiteurs de la protease m

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIAMANDIS ELEFTHERIOS P ET AL: "Human kallikrein 6 as a biomarker of Alzheimer's disease", CLINICAL BIOCHEMISTRY, vol. 33, no. 8, November 2000 (2000-11-01), pages 663 - 667, XP002339997, ISSN: 0009-9120 *
OGAWA K ET AL: "Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.", PSYCHIATRY AND CLINICAL NEUROSCIENCES. AUG 2000, vol. 54, no. 4, August 2000 (2000-08-01), pages 419 - 426, XP002339998, ISSN: 1323-1316 *
ZARGHOONI MARYAM ET AL: "Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients", CLINICAL BIOCHEMISTRY, vol. 35, no. 3, May 2002 (2002-05-01), pages 225 - 231, XP002339996, ISSN: 0009-9120 *

Also Published As

Publication number Publication date
WO2005078117A2 (fr) 2005-08-25
EP1718975A2 (fr) 2006-11-08

Similar Documents

Publication Publication Date Title
WO2005075665A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1)
WO2004104216A3 (fr) Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
WO2006008002A3 (fr) Agents diagnostiques et therapeutiques pour pathologies associees a la kallikreine 1 (klk1)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2005078117A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6)
WO2005114207A3 (fr) Diagnostic et traitement de maladies associees a l'aminopeptidase n (anpep)
WO2005022146A3 (fr) Diagnostics et traitements de maladies associees a la kallikreine 13 (klk13)
WO2005075662A3 (fr) Methodes diagnostiques et therapeutiques des maladies associees au kallikrein 2 (klk2)
WO2005118840A3 (fr) Elements diagnostiques therapeutiques pour des maladies associees a la kallikreine 10 (klk10)
WO2005085466A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 2 associee a rho (rock2)
WO2005075675A3 (fr) Outils de diagnostic et de traitement de maladies associees a la cysteine protease putative 1 (prsc1)
WO2005022164A3 (fr) Agents diagnostiques et agents therapeutiques destines a des maladies associees a la kallikreine 8 (klk8)
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2005090966A3 (fr) Diagnostic et therapeutique pour des maladies associees au recepteur delta active de la proliferation des peroxysomes (ppard)
WO2004104574A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 7 (ccr7)
WO2004104595A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd)
WO2005085469A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees a la proteine kinase 1 associee a rho (rock1)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2005021781A3 (fr) Diagnostic et traitement de maladies associees a la kallicreine 9 (klk9)
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)
WO2005095631A3 (fr) Diagnostics et therapies pour maladies associees a la kinase 4 alpha de lignee mixte (mlk4 alpha)
WO2004106934A3 (fr) Diagnostics et agents therapeutiques destines a des maladies liees au recepteur 7 de 5-hydroxytryptamine (serotonine) (5-ht7)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005707200

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005707200

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2005707200

Country of ref document: EP